e-learning
resources
London 2016
Tuesday, 06.09.2016
New signalling pathways in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Galectin-9 attenuates elastase-induced emphysema by reducing neutrophil chemotaxis in mice
Yuko Horio (Kumamoto, Japan), Yuko Horio, Keisuke Kojima, Naoki Saita, Yohei Migiyama, Aiko Masunaga, Hidenori Ichiyasu, Kazuhiko Fujii, Hirotsugu Kohrogi
Source:
International Congress 2016 – New signalling pathways in COPD
Session:
New signalling pathways in COPD
Session type:
Thematic Poster
Number:
4013
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yuko Horio (Kumamoto, Japan), Yuko Horio, Keisuke Kojima, Naoki Saita, Yohei Migiyama, Aiko Masunaga, Hidenori Ichiyasu, Kazuhiko Fujii, Hirotsugu Kohrogi. Galectin-9 attenuates elastase-induced emphysema by reducing neutrophil chemotaxis in mice. Eur Respir J 2016; 48: Suppl. 60, 4013
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Acid sphingomyelinase deficiency improves lung function in allergen-induced asthma in mice
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Effect of mast cells degranulation blockade on the inflammatory response outcome in the COPD model
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Effect of MSC treatment on LPS-induced inflammation, emphysema and atherosclerosis in E3L mice
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015
Role of CD69 in the pathogenesis of elastase-induced pulmonary inflammation and emphysema
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Autoimmune induction of a COPD-like inflammatory phenotype in mice
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013
Viral mimetic Poly(I:C) exacerbates cigarette smoke-induced pulmonary inflammation by facilitating the release of neutrophil-derived elastase
Source: International Congress 2014 – Mechanisms of COPD and inhalation injury
Year: 2014
Arginase 1 contributes to fibrogenesis in the lungs of silica-challenge mice
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Reduction of lung cytokines and luminal inflammatory cells in IL-1b deficient mice
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
T lymphocytes in cigarette-smoke induced-emphysema and bronchial remodelling
Source: International Congress 2016 – Mechanisms of disease
Year: 2016
BmTI-A: A serine protease inhibitor attenuates hyperresponsiveness in an experimental model of chronic allergic inflammation in Balb/c mice
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
A short-term model of COPD identifies a role for mast cell tryptase
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Influenza induced exacerbation is associated with steroid insensitive AHR and pulmonary inflammation in HDM-sensitised mice
Source: International Congress 2016 – Immune responses in the lung
Year: 2016
The effect of lipopolysaccharide-contaminated ovalbumin on airway inflammation and remodeling in a chronic murine asthma model
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
Cigarette smoke-induced lung inflammation is skewed in estrogen receptor-alpha deficient mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept